Scott hails FDA approval of Johnson & Johnson COVID-19 vaccine

Vermont Business Magazine Governor Phil Scott today issued the following statement with the emergency use authorization for the Johnson & Johnson COVID-19 vaccine. He also noted that Vermont has now surpassed 100,000 initial vaccines and over 50,000 have completed both doses.

“With the FDA granting emergency use authorization for the Johnson & Johnson COVID-19 vaccine, we are one step closer to putting this pandemic behind us and building back stronger than before.

“Given the limited supply of vaccine to date, Vermont’s age-banded rollout strategy has relied on the data and science with the primary objective of preserving life. We have made important progress and are already seeing fewer cases among those at highest risk. With a new vaccine coming online, we will be able to scale up our efforts, speed up our timeframes and broaden our eligibility faster.

“This is another significant step forward in our work to end this pandemic and I join many in Vermont and across the country welcoming this news.”

Of the 100,000 vaccines, Scott said, "Yesterday we reached an important milestone in our work to end the pandemic: 100,000 Vermonters have received at least their first dose. With J&J coming online this week, we will be able to scale up our efforts, speed up our timeframes and broaden our eligibility faster."

The Vermont Department of Health on Sunday is reporting 100 new cases of COVID-19 for a total of 15,198 and 204 deaths statewide.

COVID-19 in Vermont

COVID-19 VACCINE DASHBOARD

The COVID-19 Vaccine Dashboard is updated Tuesdays through Saturdays.

The data in the dashboard includes the vaccines available in Vermont (currently, Pfizer-BioNTech and Moderna). Data is based on date reported to the Vermont Immunization Registry and does not reflect date of vaccination. Information reflects counts reported by the end of the previous day. Data is subject to change.

The data in the dashboard includes the vaccines available in Vermont (currently, Pfizer-BioNTech and Moderna)